Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    23816960 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Conditions: Lung Neoplasms;   EGFR Gene Mutations
Intervention: Drug: Osimertinib
2 Not yet recruiting Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
Condition: NSCLC
Interventions: Drug: Bevacizumab;   Drug: Erlotinib
3 Active, not recruiting
Has Results
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Conditions: Carcinoma, Non-Small-Cell Lung;   Adenocarcinoma
Interventions: Drug: Pemetrexed;   Drug: BIBW 2992;   Drug: Cisplatin

Indicates status has not been verified in more than two years